Aldagen is a technology company.
Aldagen has raised $14.0M across 1 funding round.
Aldagen has raised $14.0M in total across 1 funding round.
Aldagen was a clinical-stage biopharmaceutical company focused on developing regenerative cell therapies using aldehyde dehydrogenase (ALDH) to select potent stem cells from adult sources, such as cord blood and bone marrow.[1][2][5] It targeted conditions like inherited metabolic diseases in pediatric patients (via ALD-101 in Phase III trials), critical limb ischemia (ALD-301 preparing for Phase III), ischemic heart disease, leukemia, stroke, and post-transplant reconstitution, aiming to enhance blood vessel formation and tissue repair.[1][4] The company served patients with vascular and metabolic disorders, addressing unmet needs in stem cell potency and purification to improve treatment efficacy over standard therapies.[1][3]
Founded in 2000 and headquartered in Durham, North Carolina, Aldagen raised $79.49M before being acquired by Cytomedix on February 9, 2012, after filing for an IPO; it later became a subsidiary specializing in vascular therapies.[2][5] Growth momentum included advanced clinical trials and expansion into cancer stem cell purification, but operations ceased as an independent entity post-acquisition.[1][2]
Aldagen was founded in 2000 as one of the leading adult stem cell companies advancing to clinical trials in the US, leveraging intellectual property around the ALDH enzyme to isolate high-potency hematopoietic and other stem cells from adult tissues.[1][2][5] Specific founders are not detailed in available records, but the company emerged amid early 2000s excitement in regenerative medicine, building on research showing ALDH-bright cells' superior potency for blood production and beyond.[1]
Early traction came from preclinical validation across stem cell types, leading to pivotal programs like ALD-101 for pediatric metabolic diseases—reaching Phase III by demonstrating safety and preliminary efficacy—and ALD-301 for critical limb ischemia, where purified bone marrow cells were reinjected to promote angiogenesis and avert amputations.[1] An IPO filing highlighted its momentum, but acquisition by Cytomedix in 2012 marked a key pivot, integrating its tech into broader regenerative platforms targeting vascular conditions.[1][2][3]
Aldagen rode the early 2000s stem cell therapy wave, capitalizing on ALDH as a biomarker for "supercharged" adult stem cells amid regulatory hurdles for embryonic alternatives and growing demand for vascular regenerative treatments.[1][2] Timing was ideal post-2000 genomics boom, enabling precise cell selection when crude isolation methods limited efficacy; market forces like rising ischemic diseases (e.g., diabetes-related limb loss) and pediatric metabolic unmet needs favored its pipeline.[1][4]
It influenced the ecosystem by validating enzyme-based purification, paving the way for modern cell therapies in ischemia and transplants—tech later absorbed by Cytomedix (rebranded elements in Nuo Therapeutics), contributing to commercial regenerative products.[2][3] This advanced the shift toward potent, adult-sourced cells in biotech, impacting fields like cardio-vascular repair and oncology.
Post-2012 acquisition, Aldagen's independent trajectory ended, with its ALDH platform integrated into Cytomedix's vascular therapies and successors like Nuo Therapeutics, which commercialized related cell-based healing tech as of 2015.[2][3] No recent activity suggests standalone revival, but its IP endures in regenerative medicine.
Emerging trends like AI-driven cell selection and CRISPR-enhanced stem cells could revive ALDH-like approaches for ischemia or transplants; if licensed or spun out, it might target combo therapies amid aging populations driving vascular demand. Aldagen's legacy underscores how precise stem cell tech seeded today's $50B+ regen med market—proving adult cells' viability when properly harnessed.[1][2]
Aldagen has raised $14.0M in total across 1 funding round.
Aldagen's investors include HealthQuest Capital.
Aldagen has raised $14.0M across 1 funding round. Most recently, it raised $14.0M Series C in December 2006.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2006 | $14.0M Series C | HealthQuest Capital |